Genetic clue could guide heart drug use in Post-Heart attack patients
NCT ID NCT07362966
Summary
This study is testing if a low-dose anti-inflammatory drug (colchicine) can slow the progression of coronary artery plaque in people who have recently had a heart attack. It specifically aims to see if the drug works better for patients who have a certain genetic marker called TET2-CHIP. The trial will involve 120 stable patients who will be followed for one year to measure changes in their heart plaque and blood markers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
General Hospital of Northern Theater Command
Shenyang, Liaoning, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.